Please note that the ANZCTR website will be unavailable from 9am until 9.30am (AEST) on Monday 22nd July for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00501657




Registration number
NCT00501657
Ethics application status
Date submitted
13/07/2007
Date registered
16/07/2007
Date last updated
29/10/2015

Titles & IDs
Public title
Effects of Sitagliptin on Gastric Emptying in Healthy Subjects
Scientific title
Effects of Sitagliptin on Gastric Emptying in Healthy Subjects
Secondary ID [1] 0 0
061025
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gastroparesis 0 0
Diabetes Mellitus 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Sitagliptin
Treatment: Drugs - Placebo

Experimental: Sitagliptin (100mg) - Active drug (sitagliptin)

Placebo Comparator: Placebo (sugar pill) - Inactive drug (placebo)


Treatment: Drugs: Sitagliptin
100mg mane for 2 days

Treatment: Drugs: Placebo
100mg mane for 2 days

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Gastric emptying rate
Timepoint [1] 0 0
4 hours per study
Secondary outcome [1] 0 0
Intragastric distribution, gastrointestinal hormone release (GLP-1, GIP), glycemia, insulinemia, appetite
Timepoint [1] 0 0
4 hours per study

Eligibility
Key inclusion criteria
- Male or female (females must be using an appropriate contraceptive method)

- 18 - 45 years

- Body mass index (BMI) 19 - 25 kg/m2.
Minimum age
18 Years
Maximum age
45 Years
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Exclusion criteria:

- Subjects with gastrointestinal disease, history of gastrointestinal surgery and/or
significant gastrointestinal symptoms

- Subjects taking medication known to influence gastrointestinal function

- Alcohol intake > 20 g per day

- Smoking > 10 cigarettes per day

- Pregnant and/or lactating females

- Calculated creatinine clearance < 60 ml/min

- Exposure to ionising radiation for research purposes in the previous 12 months.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
Discipline of Medicine, Royal Adelaide Hospital - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Other
Name
Royal Adelaide Hospital
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Merck Sharp & Dohme Corp.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine the effects of the drug, sitagliptin, on the rate
at which the stomach empties, and the release of gut hormones and blood glucose
concentrations, after a mashed potato meal in healthy subjects. Sitagliptin has been shown to
reduce the blood glucose (sugar) response to a meal and this may potentially be due to
slowing of stomach emptying. This is particularly relevant to people who have diabetes, in
whom normalization of elevated blood glucose levels is important to maintain health.
Trial website
https://clinicaltrials.gov/show/NCT00501657
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Karen L Jones, PhD
Address 0 0
University of Adelaide, Royal Adelaide Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications